Resource Constraints Preventing FDA From Getting Full Benefits of QbR
This article was originally published in The Gold Sheet
Executive Summary
Generic drug reviews falling behind despite new question-based-review approach due to increasing workload and declining resources, including a lack of user fees. How to improve QbR and microbiology submissions and reduce first-cycle review times. How more frequently updated dissolution and inactive ingredient databases could help.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.